[Federal Register Volume 65, Number 154 (Wednesday, August 9, 2000)]
[Notices]
[Pages 48724-48725]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-20039]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.

[[Page 48725]]

    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, ``Pharmacokinetic and Pharmacodynamic Studies for 
Medication Development.''
    Date: August 9, 2000.
    Time: 9:30 a.m. to 12 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: Neuroscience Center, National Institutes of Health, 6001 
Executive Blvd., Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Eric Zatman, Contract Review Specialist, Office 
of Extramural Affairs, National Institute on Drug Abuse, National 
Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 
9457, Bethesda, MD 20892-9547, (301) 435-1438.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse Research Programs, National Institutes of Health, 
HHS)

    Dated: August 1, 2000.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 00-20039 Filed 8-8-00; 8:45 am]
BILLING CODE 4140-01-M